Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics Inc. develops antibody-based medicines as a clinical-stage biotechnology company. Its updates center on antibody discovery and development programs in endocrinology, women’s health, immunology, oncology, and other areas, including work on complex targets such as GPCRs and ion channels.
Recurring news themes include clinical disclosures for ABCL635, an antibody therapeutic targeting NK3R for the non-hormonal treatment of moderate-to-severe vasomotor symptoms associated with menopause. Company announcements also cover financial results, earnings-call materials, investor conference participation, platform and manufacturing updates, and patent licensing or litigation-resolution developments.
AbCellera (Nasdaq: ABCL) announced that its second antibody, LY-CoV1404, has commenced clinical trials for treating patients with mild-to-moderate COVID-19. The ongoing BLAZE-4 trials, conducted with Eli Lilly, will assess LY-CoV1404 both solo and in combination with other antibodies. Preclinical results demonstrate that LY-CoV1404 effectively binds to a stable region of the SARS-CoV-2 spike protein, neutralizing all known variants of concern. This potent antibody may enable lower clinical dosing and potentially subcutaneous administration, supporting its role in combating COVID-19 long-term.
AbCellera (Nasdaq: ABCL) has commenced construction on an expanded global headquarters in Vancouver, aiming to grow its workforce from 250 to hundreds over the next few years. The new tech campus will span 380,000 square feet and is projected for completion in 2023 and 2024. CEO Carl Hansen emphasized that the facilities will accelerate antibody therapy development in collaboration with global biotech and pharma partners. This development solidifies Vancouver's position as an innovation hub and supports AbCellera's long-term goal of establishing Canada's first clinical-grade antibody manufacturing facility.
AbCellera (Nasdaq: ABCL) will release its first-quarter 2021 financial results on May 13, 2021, and host an earnings conference call at 2:00 p.m. PT (5:00 p.m. ET). A live webcast will be accessible via the Investor Relations website, with a replay available afterward.
AbCellera specializes in antibody discovery by analyzing immune systems, partnering with various drug developers to streamline drug development processes.
AbCellera (Nasdaq: ABCL) and Empirico Inc. announced a strategic collaboration focusing on multi-target drug discovery. The partnership utilizes advanced technologies and data analysis to identify therapeutic targets and antibodies. Empirico will select up to five targets using its Precision Insights Platform, while AbCellera will leverage its AI for antibody discovery. AbCellera will receive research payments and may earn royalties from developed products. The collaboration aims to address challenges in drug development by linking human genetics to therapy insights.
AbCellera (Nasdaq: ABCL) announced the publication of preclinical data in Science Translational Medicine demonstrating the high potency of bamlanivimab (LY-CoV555) against SARS-CoV-2. The findings indicate that bamlanivimab significantly reduces viral load post-exposure, highlighting its potential to decrease viral shedding and transmission. In clinical trials, bamlanivimab has shown to cut hospitalizations by 70% in high-risk COVID-19 patients. It has also been authorized in over 15 countries and supports ongoing efforts to develop next-generation antibodies.
AbCellera (Nasdaq: ABCL) has announced an expanded collaboration with Gilead Sciences that includes a multi-year, multi-target antibody discovery initiative and access to AbCellera's Trianni Mouse® technology. The agreement entails upfront payments, milestone payments, and royalties based on the commercialization of antibodies developed. AbCellera will produce panels of antibodies for up to eight new targets across various indications, enhancing drug development efficiency with advanced technology.
AbCellera (Nasdaq: ABCL) announced positive results from a Phase 3 trial of bamlanivimab and etesevimab, reducing COVID-19-related hospitalizations and deaths by 87% in high-risk patients. No deaths occurred in the treatment group, while 14 were reported in the placebo cohort. Milestones achieved include Emergency Use Authorization from the FDA and expanded access in the EU. The study involved 769 patients, showing a safety profile consistent with earlier trials. Bamlanivimab was the first COVID-19 therapeutic candidate to receive FDA EUA.
AbCellera (Nasdaq: ABCL) announced a positive scientific opinion from the EMA's CHMP for the use of bamlanivimab alone and in combination with etesevimab for treating COVID-19 in high-risk patients aged 12 and older. This recommendation allows EU member states to make informed decisions on therapy usage before market authorization. The CHMP opinion was backed by positive results from Eli Lilly's BLAZE-1 trial, showing a 70% reduction in hospitalization rates. Bamlanivimab has also received authorization in over 10 countries and generated $871 million in sales in 2020.
AbCellera (NASDAQ: ABCL) will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 1:20 p.m. PT. A live audio webcast will be accessible on AbCellera’s Investor Relations website, with a replay available afterward. AbCellera is a technology company focused on discovering antibodies from natural immune systems, partnering with drug developers to accelerate drug development and reduce costs. The press release includes forward-looking statements about potential risks and uncertainties in their business operations.
AbCellera (Nasdaq: ABCL) has appointed Ester Falconer, Ph.D., as Chief Technology Officer effective January 28, 2021. Dr. Falconer will oversee the company's strategy to enhance therapeutic antibody discovery technologies. Previously, she led R&D at AbCellera and contributed significantly to the development of the COVID-19 therapeutic bamlanivimab. Her appointment is expected to strengthen leadership and innovation within the company. Dr. Falconer has been with AbCellera since 2015, advancing through various roles, and holds a Ph.D. in genetics and cell biology.